Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...
The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) for patients with newly ...
Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Smoldering multiple myeloma is a complex, intermediary stage ...
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...
ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...
Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated ...
D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
The FDA approved a new DARZALEX FASPRO combination therapy for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. The decision expands DARZALEX FASPRO’s ...
How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...
STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results